TNP-470

Generic Name: TNP-470

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₈ClNO_₆

CAS Number: 129298-91-5

Unique Ingredient Identifier: X47GR46481

Background: O-(chloroacetylcarbamoyl)fumagillol (TNP-470) has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, and Pancreatic Neoplasms.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas

Phase 2

Terminated

Conditions: Pancreatic Neoplasms

Interventions: Drug: TNP-470

First Posted Date: 2002-06-05

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00038701

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma

Phase 1

Completed

Conditions: Sarcoma, Kaposi
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 42

Registration Number: NCT00000763

Locations: 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States

and more 3 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy